ACADIA Pharmaceuticals (NASDAQ:ACAD) Issues Earnings Results

ACADIA Pharmaceuticals (NASDAQ:ACAD) posted its quarterly earnings results on Wednesday. The biopharmaceutical company reported $0.17 EPS for the quarter, beating the consensus estimate of $0.13 by $0.04, Zacks reports. ACADIA Pharmaceuticals had a return on equity of 25.83% and a net margin of 13.83%.

ACADIA Pharmaceuticals Stock Performance

ACADIA Pharmaceuticals stock traded down $0.06 during mid-day trading on Wednesday, reaching $18.96. The company’s stock had a trading volume of 1,291,043 shares, compared to its average volume of 2,803,573. The business’s 50 day simple moving average is $18.28 and its 200 day simple moving average is $16.78. The company has a market capitalization of $3.15 billion, a price-to-earnings ratio of 24.30 and a beta of 0.37. ACADIA Pharmaceuticals has a 12 month low of $14.15 and a 12 month high of $26.56.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. HC Wainwright restated a “buy” rating and set a $27.00 target price on shares of ACADIA Pharmaceuticals in a research report on Thursday, November 7th. StockNews.com downgraded ACADIA Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 14th. Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 price target on shares of ACADIA Pharmaceuticals in a research note on Thursday, November 7th. Guggenheim cut shares of ACADIA Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $23.00 to $20.00 in a research note on Friday, January 3rd. Finally, Deutsche Bank Aktiengesellschaft started coverage on shares of ACADIA Pharmaceuticals in a research report on Tuesday, February 11th. They set a “hold” rating and a $22.00 target price for the company. Eight research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, ACADIA Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $24.00.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.